On July 29th, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the USA. The launch will be carried out through a collaboration with Pangea Laboratory LLC (“Pangea”), which will conduct the analyses in its CLIA-certified, CAP-accredited laboratory in Tustin, California, while Genetic Analysis will generate revenues through the sale of reagent kits.

In conclusion, Analyst Group views the launch of GA-map® MHI GutHealth in the U.S. as a strategically important step for Genetic Analysis. While short-term financial impact may be limited due to a gradual sales ramp-up, the collaboration with Ferring Pharmaceuticals and the test’s application in addressing recurrent Clostridioides difficile infections underscore a strong long-term potential through a diagnostic approach on the human microbiome market. With a clinically validated biomarker, increasing demand for standardized microbiome diagnostics, and expected future use in treatment monitoring, the launch positions Genetic Analysis to capture value in a growing and clinically relevant market segment.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group

This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Läs mer på MFN